60. 再生不良性貧血
[臨床試験数:218,薬物数:362(DrugBank:81),標的遺伝子数:39,標的パスウェイ数:155

Searched query = "Aplastic anemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
9 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR1900026462
2019-08-192019-10-11Clinical study for umbilical cord blood mesenchymal stem cells combined with peripheral blood stem cells co-transplantation with reduced PT-Cy in the prevention of GVHD in the treatment of aplastic anemiaClinical study for umbilical cord blood mesenchymal stem cells combined with peripheral blood stem cell co-transplantation with reduced PT-Cy in the prevention of GVHD in the treatment of aplastic anemia--single-center, single-arm, open clinical study aplastic anemia,AACass series:low dose post Cyclophosphamide and Mesenchymal stem cell;Cancer Hospital Affiliated to Zhengzhou University-He'nan Cancer HospitalNULLRecruitingBothCass series:20;China
2NCT03055078
(ClinicalTrials.gov)
January 20174/2/2017Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Aplastic AnemiaEvaluation of Safety and Efficacy in Patients With Aplastic Anemia by Transplantation of Umbilical Cord Derived Mesenchymal Stem CellsAplastic AnemiaBiological: mesenchymal stem cellsHebei Medical UniversityNULLRecruiting14 Years60 YearsAll10Phase 1China
3NCT02407470
(ClinicalTrials.gov)
January 201525/3/2015Safety and Efficacy of Patient's Own AD-MSC and AD-HSC Transplantation in Patients With Severe Aplastic AnemiaA Multicenter, Randomized, Controlled Study of the Efficacy and Safety of the Combination of Adipose Tissue-derived Hematopoietic Stem Cells (AD-HSCs) and ATG in the Treatment of Severe Aplastic AnemiaSevere Aplastic AnemiaDrug: Rabbit antithymoglobulin (ATG);Procedure: Adipose derived mesenchymal stem cells ( AD-MSCs);Procedure: AD-MSC transdifferentiated HSCs (AD-HSCs)Navy General Hospital, BeijingPeking Union Medical College Hospital;General Hospital of Beijing PLA Military Region;Chinese Academy of Medical SciencesRecruiting14 Years70 YearsBoth90Phase 1/Phase 2China
4NCT02218437
(ClinicalTrials.gov)
October 20136/8/2014Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells(Umbilical Cord Derived)Child With Severe Aplastic Anemia (SAA) Therapy: the Injection of Umbilical Cord Derived Mesenchymal Stem Cells.Complications of Organ Transplant Stem Cells Umbilical CordDrug: MSC+ATGChinese Academy of Medical SciencesNULLRecruiting1 Month18 YearsBoth20Phase 4China
5NCT02247973
(ClinicalTrials.gov)
February 201317/9/2014Mesenchymal Stem Cells Co-transplantation in Alternative Donor Transplantation of Severe Aplastic Anemia.Phase?Trial of Co-transplantation With Bone Marrow Derived Mesenchymal Stem Cells From Related Donors in Alternative Donor Transplantation of Severe Aplastic Anemia.Severe Aplastic AnemiaBiological: mesenchymal stem cellsGuangzhou General Hospital of Guangzhou Military CommandGuangzhou First Municipal People’s Hospital;Nanfang Hospital of Southern Medical University;Southern Medical University, China;First Affiliated Hospital, Sun Yat-Sen University;Second Affiliated Hospital, Sun Yat-Sen University;Third Affiliated Hospital, Sun Yat-Sen University;Fifth Affiliated Hospital, Sun Yat-Sen University;Guangdong General Hospital;The Second People's Hospital of GuangDong Province;First Affiliated Hospital of Jinan University;The First Affiliated Hospital of Guangzhou Medical University;Second Affiliated Hospital of Guangzhou Medical University;Peking University Shenzhen Hospital;Shenzhen Second People's HospitalEnrolling by invitation14 Years50 YearsBoth100Phase 2China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01297972
(ClinicalTrials.gov)
February 201116/2/2011Mesenchymal Stem Cells in the Treatment of Relapsed/Refractory Severe Acquired Aplastic AnemiaBone Marrow Mesenchymal Stem Cells in the Treatment of Refractory Severe Acquired Aplastic AnemiaAplastic AnemiaBiological: Intravenous bone marrow mesenchymal stem cells infusionUniversity of Sao PauloNULLCompleted18 Years65 YearsBoth9Phase 1/Phase 2Brazil
7NCT01305694
(ClinicalTrials.gov)
February 201128/2/2011Mesenchymal Stem Cells Transplantation to Patients With Relapsed/Refractory Aplastic Anemia.Phase?/?Trial of Bone Marrow Derived Mesenchymal Stem Cell Transplantation From Related Donor to Patients With Relapsed/Refractory Aplastic Anemia.Aplastic AnemiaBiological: bone marrow derived mesenchymal stem cellsGuangzhou General Hospital of Guangzhou Military CommandGuangzhou Municipal Twelfth People's Hospital;Guangdong Prevention and Treatment Center for Occupational DiseasesRecruiting16 YearsN/ABoth50Phase 1/Phase 2China
8NCT01182662
(ClinicalTrials.gov)
August 201011/8/2010Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Severe Aplastic AnemiaPhase II Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat SAAAplastic AnemiaOther: Human umbilical cord-derived MSCs and cyclosporin A;Other: cyclosporin AShandong UniversityNational Natural Science Foundation of ChinaRecruiting18 Years80 YearsBoth30Phase 2China
9EUCTR2008-005594-35-BE
(EUCTR)
28/10/200906/08/2009Randomized double-blind study of mesenchymal stem cells (MSC) in patients undergoing matched unrelated allogeneic bone marrow or peripheral blood stem cell transplantation- A European multicentre study. - NARandomized double-blind study of mesenchymal stem cells (MSC) in patients undergoing matched unrelated allogeneic bone marrow or peripheral blood stem cell transplantation- A European multicentre study. - NA Hematological disorders of the following types:ALL: acute lymphoblastic leukemia in complete remission (<5% blasts in marrow) up to and including third remission (excluding relapse).AML: acute myelocytic leukemia in remission (excluding relapse).CML: chronic myelocytic leukemia who are in the chronic phase of the disease.Severe aplastic anemia, hemoglobinopathies (thalassemia major).Inborn errors of metabolism.Myelodysplastic syndromes
MedDRA version: 9.1;Level: LLT;Classification code 10027703;Term: Mismatched donor bone marrow transplantation therapy
Product Name: Mesenchymal stem cells
Product Code: MSC
CHU Sart-TilmanNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
172Belgium